Efficacy and Safety of Adding Empagliflozin to Liraglutide on Renal Function in Patients with Advanced-Stage Type 2 Diabetic Kidney Disease: A Randomized Controlled Trial
Empagliflozin increased hemoglobin concentration and decreased body weight in patients with advanced-stage type 2 diabetic kidney disease who received liraglutide. However, empagliflozin did not provide short-term benefits with regard to renal function decline, urinary protein excretion, or glycemic control in these patients.
Authors
- Isao Komesu
- Kenji Sunagawa (ORCID: https://orcid.org/0000-0003-0365-4619)
- Norifumi Kamiya (ORCID: https://orcid.org/0000-0002-7424-1582)
- Yuki Sunagawa (ORCID: https://orcid.org/0000-0002-3666-1607)
- Keiji Hirai (ORCID: https://orcid.org/0000-0002-6899-2478)
- Sumito Sunagawa (ORCID: https://orcid.org/0000-0002-5937-3755)
- Aizan Hirai
- Yoshiyuki Morishita (ORCID: https://orcid.org/0000-0001-8979-9442)
- Ken Nakachi
- Susumu Ookawara
- Hiroshi Sunagawa
Institutions
- Jichi Medical University (JP)
- University of the Ryukyus (JP)
- Okinawa Prefectural Chubu Hospital (JP)
- Chiba Cerebral and Cardiovascular Center (JP)
- Sunagawa City Medical Center (JP)
- Jichi Medical University Saitama Medical Center (JP)
Publication Details
- Journal
- Diabetes Metabolic Syndrome and Obesity
- Published
- 2024-10-01
- DOI
- https://doi.org/10.2147/dmso.s471535
- Citations
- 2
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.72